New hope for deadly lung complication after transplant
NCT ID NCT03805477
Summary
This study is testing whether adding the drug Nintedanib to standard treatment is safe and tolerable for patients who develop severe lung scarring (BOS) after a stem cell transplant. The trial will enroll 20 participants who will take Nintedanib daily for 12 months. Researchers will monitor side effects and see if the drug helps slow the decline in lung function associated with this serious condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS OBLITERANS SYNDROME (BOS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinic of Hematology, University Hospital Basel
RECRUITINGBasel, 4031, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Clinic of Respiratory Medicine, University Hospital Basel
RECRUITINGBasel, 4031, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
King Faisal Specialist Hospital & Research Centre
RECRUITINGRiyadh, 11471, Saudi Arabia
Contact
Conditions
Explore the condition pages connected to this study.